C4 Therapeutics, ordinary share
CCCC, US12529R1077

C4 Therapeutics, Inc. is a pharmaceutical company that develops technology in the field of targeted protein degradation for the treatment of cancer. The company's goal is to create a new generation of low-molecular-weight medicines used to treat a large number of diseases, including cancer.

The company is developing the Degronimid platform, which allows you to target and destroy proteins that cause diseases. After the destruction of proteins, a remedy from C4 Therapeutics, Inc. promotes the elimination of destroyed pathogenic proteins from the cells of the body.

The company's leading product is the drug CFT7455. At the moment, it has passed half of the clinical trials, and after they are fully completed, it should become a full-fledged treatment for cancerous tumors.

The company works in partnership with the following companies: F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC.

The company was established in 2015 and is headquartered in Watertown, Massachusetts.

The company conducted an IPO of its shares on the NASDAQ stock exchange under the CCCC ticker on October 2, 2020 at a price of $26.6 per share.